指南与共识消化系统肿瘤

晚期胃食管癌的免疫治疗与靶向治疗:ASCO指南

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2023-01-05

美国临床肿瘤学会(ASCO)召集专家小组系统综述18项随机对照试验,制定晚期胃食管癌靶向治疗推荐。指南按HER2状态、PD-L1评分(CPS或TPS)、组织学类型及治疗线数给出免疫联合化疗或双免疫、抗HER2联合免疫等推荐,并推荐患者参加临床试验。

要点

  • HER2阴性胃腺癌且PD-L1 CPS≥5,推荐一线纳武利尤单抗联合化疗。
  • HER2阴性食管或胃食管结合部腺癌且PD-L1 CPS≥10,推荐一线帕博利珠单抗联合化疗。
  • HER2阳性胃或胃食管结合部腺癌一线,推荐曲妥珠单抗联合帕博利珠单抗并联合化疗。

核心结论

  • 指南针对晚期胃食管癌按HER2状态、PD-L1评分、组织学类型及治疗线数推荐免疫治疗与靶向治疗方案。
  • 专家组认为胃食管癌的靶向治疗选择将持续演变,推荐所有患者参加临床试验。

研究设计与样本

  • 美国临床肿瘤学会(ASCO)召集专家小组,对相关研究进行系统综述并制定临床实践推荐。
  • 18项随机对照试验符合系统综述的纳入标准。

主要发现

  • 系统综述纳入18项随机对照试验,为各项推荐提供依据。

关键数值与推荐

  • HER2阴性胃腺癌且PD-L1 CPS≥5:推荐一线纳武利尤单抗联合化疗。
  • HER2阴性食管或胃食管结合部腺癌且PD-L1 CPS≥5:推荐一线纳武利尤单抗联合化疗。
  • HER2阴性食管或胃食管结合部腺癌且PD-L1 CPS≥10:推荐一线帕博利珠单抗联合化疗。
  • 食管鳞状细胞癌且PD-L1 TPS≥1%:推荐纳武利尤单抗联合化疗,或纳武利尤单抗联合伊匹木单抗;PD-L1 CPS≥10:推荐帕博利珠单抗联合化疗。
  • HER2阳性胃或胃食管结合部腺癌初治不可切除或转移:推荐曲妥珠单抗联合帕博利珠单抗并联合化疗;一线进展后HER2阳性:推荐德曲妥珠单抗;晚期胃食管或胃食管结合部腺癌一线进展后:推荐雷莫西尤单抗联合紫杉醇。

临床怎么用

  • 按HER2状态、PD-L1 CPS或TPS评分、组织学类型及治疗线数选择相应的免疫联合化疗、双免疫或抗HER2靶向方案。
  • 专家组推荐所有患者参加临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer. METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Eighteen randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS: For human epidermal growth factor receptor 2 (HER2)-negative patients with gastric adenocarcinoma (AC) and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 5, first-line therapy with nivolumab and chemotherapy (CT) is recommended. For HER2-negative patients with esophageal or gastroesophageal junction (GEJ) AC and PD-L1 CPS ≥ 5, first-line therapy with nivolumab and CT is recommended. First-line therapy with pembrolizumab and CT is recommended for HER2-negative patients with esophageal or GEJ AC and PD-L1 CPS ≥ 10. For patients with esophageal squamous cell carcinoma and PD-L1 tumor proportion score ≥ 1%, nivolumab plus CT, or nivolumab plus ipilimumab is recommended; for patients with esophageal squamous cell carcinoma and PD-L1 CPS ≥ 10, pembrolizumab plus CT is recommended. For patients with HER2-positive gastric or GEJ previously untreated, unresectable or metastatic AC, trastuzumab plus pembrolizumab is recommended, in combination with CT. For patients with advanced gastroesophageal or GEJ AC whose disease has progressed after first-line therapy, ramucirumab plus paclitaxel is recommended. For HER2-positive patients with gastric or GEJ AC who have progressed after first-line therapy, trastuzumab deruxtecan is recommended. In all cases, participation in a clinical trial is recommended as it is the panel's expectation that targeted treatment options for gastroesophageal cancer will continue to evolve.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. J Clin Oncol. 2023. PMID: 36603169. doi:10.1200/JCO.22.02331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。